# Resource Summary Report

Generated by RRID on Sep 8, 2026

## VAL

RRID:CVCL_1819
Type: Cell Line

### Proper Citation

RRID:CVCL_1819

### Cell Line Information

**URL:** https://web.expasy.org/cellosaurus/CVCL_1819

**Proper Citation:** RRID:CVCL_1819

**Description:** Cell line VAL is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Diffuse large B-cell lymphoma

**Defining Citation:** PMID:8220427, PMID:8558920, PMID:16960149, PMID:19358282, PMID:20454443, PMID:26727417, PMID:27397505, PMID:28196595, PMID:30894373, PMID:31160637, PMID:35839778

**Comments:** Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** VAL

**Cross References:** CLO:CLO_0037067, EFO:EFO_0022344, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioSample:SAMN03473489, cancercelllines:CVCL_1819, Cell_Model_Passport:SIDM00416, Cosmic:1086346, Cosmic:1517631, Cosmic:1541908, Cosmic:2276320, Cosmic:2297002, Cosmic:2590022, Cosmic-CLP:1331048, DepMap:ACH-001703, DSMZ:ACC-586, DSMZCellDive:ACC-586, EGA:EGAS00001000978, GDSC:1331048, GEO:GSM115973, GEO:GSM201349,

GEO:GSM1035309, GEO:GSM1670570, LINCS_LDP:LCL-1915, Lonza:1237, PharmacoDB:VAL_1652_2019, PRIDE:PXD030304, Progenetix:CVCL_1819, Wikidata:Q54992842

**ID:** CVCL_1819

**Record Creation Time:** 20220427T221707+0000

**Record Last Update:** 20260905T182719+0000

## Ratings and Alerts

No rating or validation information has been found for VAL.

No alerts have been found for VAL.

## Data and Source Information

**Source:** Cellosaurus

## Usage and Citation Metrics

We found 6 mentions in open access literature.

**Listed below are recent publications.** The full list is available at RRID .

Tang E, et al. (2026) Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer immunology research, 14(8), 1292.

Mani R, et al. (2025) TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas. iScience, 28(6), 112584.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell, 188(2), 331.

Mehdi SH, et al. (2024) Development of New Diffuse Large B Cell Lymphoma Mouse Models. Cancers, 16(17).

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Parvin S, et al. (2019) LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL. Cancer cell, 36(3), 237.